News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ) Drug Shines in Trial Against Standard Lung-clot Drugs


3/26/2012 8:42:51 AM

Johnson & Johnson’s blood thinner Xarelto worked as well as standard treatment in preventing the recurrence of blood clots in the lung with half the risk of severe bleeding, a study found. The 4,833-patient study, sponsored by J&J and its partner Bayer AG (BAYN), found that the new blood thinner could safely and effectively replace a more complicated two drug regimen used to treat patients suffering symptoms of potentially life- threatening blood clots in the lungs. The finding, presented at the American College of Cardiology in Chicago today, could add to a lucrative market for Xarelto, approved last year for preventing strokes in patients with irregular heart rhythms.

Read at Bloomberg
Read at nj.com
Read at Fox News
Read at RTT News
Read at Chicago Tribune


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES